Stocks · News reference
Stifel Maintains Buy on Incyte, Raises Price Target to $157
Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123
JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.